Hu H, et al. - Authors assessed the clinical features, treatment, and prognosis of retinoblastoma patients with central nervous system (CNS) metastasis in Beijing Tongren Hospital, one of the largest tertiary eye centers in China. Meningeal involvement was seen in 56.6% subjects, an intracranial mass was seen in 38.7%, thickened optic nerve in 35.5%, and 16.1% presented with concurrent meningeal and spinal cord membrane involvement. On the blood and CSF, laboratory examinations were performed for patients who had received 6 cycles of systemic chemotherapy, suggesting that after chemotherapy the serum level of neurone-specific enolase (NSE) was significantly lower than that before chemotherapy. At the end of the follow-up, experts noted that 25 patients were dead with a median survival time of 6 months, and 6 cases were alive and continued to receive treatment. Results were noted to be consistent with previous reports. It could be guidance for clinical treatment, prognosis and prevention of CNS metastases in retinoblastoma.